Tumor treatment strategies based on the cGAS-STING pathway are gradually being developed, and increasing evidence shows that cGAS-STING agonists can effectively eliminate tumors and induce durable anti-tumor immune responses when combined with immunotherapy [87,88]. This evidence concerns the gene STING1 and neoplasm.